EUDA Health (NASDAQ: EUDA) outlines oncology cell therapy plan
Rhea-AI Filing Summary
EUDA Health Holdings Limited describes a planned collaboration under a non-binding Memorandum of Understanding with GO POSB Organoids Pte Ltd and Shenzhen Innovation Immunotechnology Co., Ltd. The parties plan to combine GO POSB’s induced pluripotent stem cell platform and universal tumor organoid bank with SIIT’s Natural Killer and NK-TCR cell engineering and GMP manufacturing capabilities to explore off-the-shelf cell therapies for wellness and oncology.
The initiative targets future global distribution, subject to definitive agreements, sufficient funding, manufacturing, testing, clinical evaluation and regulatory approvals. EUDA positions this program within its strategy as a distributor of wellness and non-invasive healthcare products in Asia, aiming to address the needs of over 1.8 billion people in a region where more than 30% of the population is rapidly aging.
Positive
- None.
Negative
- None.
Key Figures
Key Terms
induced pluripotent stem cell medical
Natural Killer medical
NK-TCR cell engineering medical
GMP manufacturing technical
non-binding Memorandum of Understanding regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What collaboration did EUDA (EUDA) announce in July 2026?
Is EUDA (EUDA)’s new cell therapy agreement legally binding?
What technologies are involved in EUDA (EUDA)’s integrated cell therapy program?
How does this collaboration fit EUDA (EUDA)’s stated healthcare strategy?
What is the development stage of the therapies in EUDA (EUDA)’s proposed program?
Which markets does EUDA (EUDA) currently focus on for its wellness products?
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of July 2026
Commission File Number: 001-40678
EUDA Health Holdings Limited
(Exact Name of Registrant as Specified in its Charter)
60 Kaki Bukit Place, #03-01 Eunos Techpark, Singapore 415979
(Address of Principal Executive Offices and Zip Code)
Registrant’s telephone number, including area code: +65 6327 1110
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐
Other Events.
On July 30, 2026, EUDA Health Holdings Limited issued the press release furnished herewith as Exhibit 99.1.
Exhibits
| 99.1 | Press release dated July 30, 2026. |
| 2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
| Dated: July 31, 2026 | ||
| EUDA Health Holdings Limited | ||
| By: | /s/ Alfred Lim | |
| Name: | Alfred Lim | |
| Title: | Chief Executive Officer | |
| 3 |
Exhibit 99.1
EUDA Health Announces Collaboration to Advance an Integrated iPSC Cell Therapy Program for Oncology and Wellness • Targets global distribution for innovative Oncology products
SINGAPORE, July 30, 2026 (GLOBE NEWSWIRE) — EUDA Health Holdings Limited (NASDAQ: EUDA) a Singapore-based distributor of third-party provided wellness and non-invasive healthcare products and services in Asia, with a focus on Singapore, Malaysia and China, today provided important additional details of the integrated cell therapy program to be pursued under its recently announced non-binding Memorandum of Understanding (MOU) with GO POSB Organoids Pte Ltd (“GO POSB”) and Shenzhen Innovation Immunotechnology Co., Ltd. (“SIIT”).
Subject to the execution of definitive agreements and applicable regulatory approvals, parties plan to combine GO POSB’s proprietary induced pluripotent stem cell (“iPSC”) platform and clinical-grade universal tumor organoid bank with SIIT’s Natural Killer (“NK”) and NK-TCR cell engineering capabilities and GMP manufacturing expertise to explore for the future development, manufacturing and commercialization of a new generation of off-the-shelf cell therapies for both wellness and oncology applications.
Under the MOU:
| ● | EUDA intends to bring together GO POSB and SIIT, fund the joint collaboration, facilitate the commercialization of the contemplated technologies and support global market access. |
| ● | GO POSB intends to provide access to its proprietary iPSC platform, including its clinical-grade universal tumor organoid bank, and support commercialization activities relating to the contemplated technologies. |
| ● | SIIT intends to provide access to its NK and NK-TCR cell engineering capabilities, including directed differentiation of iPSCs into NK cells, genetic engineering, functional maturation, GMP-compliant manufacturing and pre-release testing at its Shenzhen facility. |
The MOU was signed on July 15, 2026. Parties plan to leverage their complementary capabilities in regenerative medicine to support the future commercialization of next-generation cell therapy technologies.
Alfred Lim, Chief Executive officer of EUDA commented: “The details of this collaborative agreement are important for everyone to understand. We are extremely pleased to have been able to assemble this incredible team. To have an off the shelf product demonstrate effective treatment could be a game changer in this large market. Once launched, these products will offer a significant improvement over what is currently available. The three parties to the agreement offer specialized expertise and are key to bringing a product of this importance to the market globally. We intend to aggressively build value for shareholders through this initiative.”
The technologies contemplated under the proposed collaboration are under development and investigational. Commercial availability of any future products or therapies will be subject to the sufficient funding of the program, completion of manufacturing, testing, clinical evaluation and applicable regulatory approvals in the relevant jurisdictions.
About EUDA Health Holdings Limited
EUDA Health Holdings Limited (NASDAQ: EUDA) is a Singapore-based distributor of third-party provided wellness and non-invasive healthcare products and services in Asia, with a focus on Singapore, Malaysia and China. The Company aims to become a market leading distributor of non-invasive and preventive healthcare, with a strategic focus on the fast-growing longevity sector. Our mission is to address the evolving healthcare needs of over 1.8 billion people across the region which is experiencing significant demographic shifts as more than 30% of the population ages rapidly. By facilitating access to innovative, accessible, and science-backed third-party wellness and non-invasive healthcare products and services, EUDA is positioned to help with the transformation of regional healthcare from reactive medical treatment to proactive, longevity-focused care. EUDA also runs a Singapore-based property management business.
Forward-Looking Statements
Certain statements in this press release that are not historical facts constitute “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Any statements that refer to expectations or other characterizations of future events, circumstances or results are forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. The factors may include, but not be limited to, factors related to the Company’s anticipated growth strategies, future business development, ability to launch new products, enter into distribution agreements or strategic alliances with third parties, expand to other related industries or markets, and other information contained in the Company’s annual reports on Form 20-F, and detailed from time to time in the filings and future filings with the United States Securities and Exchange Commission. The views expressed are those of management and are based on currently available information. Estimates and projections contained herein have been prepared by management and involve significant elements of subjective judgment and analysis and are based on certain assumptions. No representation nor warranty, expressed or implied, is made as to the accuracy or completeness of the information contained in this document, and nothing contained herein is, or shall be relied upon, as a promise or representation, whether as to the past or the future. You are cautioned not to place undue reliance on these forward-looking statements. The Company undertakes no obligation to update these statements for revisions or changes after the date of this press release, except as required by law.
This press release is intended solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy the Company’s stock. This press release is based upon information available to the public, as well as other information from sources which management believes to be reliable, but is not guaranteed by the Company as being accurate nor does it purport to be complete. Opinions expressed herein are those of management as of the date of publication and are subject to change without notice.
Christensen Advisory
Christian Arnell
Phone: + 852 2117 0861
Email: christian.arnell@christensencomms.com